The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases.

Autor:	Liau LL; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia., Al-Masawa ME; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia., Koh B; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia., Looi QH; Future Cytohealth Sdn Bhd, Bandar Seri Petaling, Kuala Lumpur, Malaysia., Foo JB; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia., Lee SH; School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia., Cheah FC; Department of Paediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia., Law JX; Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
Jazyk:	angličtina
Zdroj:	Frontiers in pediatrics [Front Pediatr] 2020 Nov 04; Vol. 8, pp. 591693. Date of Electronic Publication: 2020 Nov 04 (Print Publication: 2020).
DOI:	10.3389/fped.2020.591693
Abstrakt:	Mesenchymal stromal cells (MSCs) can be derived from various tissue sources, such as the bone marrow (BMSCs), adipose tissue (ADSCs), umbilical cord (UC-MSCs) and umbilical cord blood (UCB-MSCs). Clinical trials have been conducted to investigate the potential of MSCs in ameliorating neonatal diseases, including bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC). In preclinical studies, MSC therapy has been tested for the treatment of various neonatal diseases affecting the heart, eye, gut, and brain as well as sepsis. Up to date, the number of clinical trials using MSCs to treat neonatal diseases is still limited. The data reported thus far positioned MSC therapy as safe with positive outcomes. However, most of these trials are still preliminary and generally smaller in scale. Larger trials with more appropriate controls and a longer follow-up period need to be conducted to prove the safety and efficacy of the therapy more conclusively. This review discusses the current application of MSCs in treating neonatal diseases, its mechanism of action and future direction of this novel therapy, including the potential of using MSC-derived extracellular vesicles instead of the cells to treat various clinical conditions in the newborn. (Copyright © 2020 Liau, Al-Masawa, Koh, Looi, Foo, Lee, Cheah and Law.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu